We are live on ! Find out more
SWTX

SpringWorks Therapeutics
SWTX

Delisted

SWTX was delisted on the 30th of June, 2025.

Back to rankings

3 hedge funds and large institutions have $2.16M invested in SpringWorks Therapeutics in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 217 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 222 → 3 (-219)

99.54% less ownership

Funds ownership: 99.59% → 0.05% (-100%)

100% less capital invested

Capital invested by funds: $3.53B → $2.16M (-$3.52B)

100% less funds holding in top 10

Funds holding in top 10: 18 → 0 (-18)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 217

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
3
Holders Change
-219
Holders Change %
-98.65%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
-18
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
217
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$341M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$335M
3
GCL
Glazer Capital LLC
New York
-$193M
4
Fidelity International
Fidelity International
Bermuda
-$142M
5
State Street
State Street
Massachusetts
-$141M
Name Holding Trade Value Shares
Change 		Change in
Stake
DekaBank Deutsche Girozentrale
1
DekaBank Deutsche Girozentrale
Germany
$2.16M – – –
Osaic Holdings
2
Osaic Holdings
Arizona
$3.9K -$103K -2,183 -96%
HNB
3
Huntington National Bank
Ohio
$47 -$20.8K -442 -100%
BlackRock
4
BlackRock
New York
– -$341M -7,260,644 Closed
Vanguard Group
5
Vanguard Group
Pennsylvania
– -$335M -7,131,004 Closed
GCL
6
Glazer Capital LLC
New York
– -$193M -4,107,199 Closed
Fidelity International
7
Fidelity International
Bermuda
– -$142M -3,013,959 Closed
State Street
8
State Street
Massachusetts
– -$141M -2,994,000 Closed
TAL
9
TIG Advisors LLC
New York
– -$123M -2,611,074 Closed
Goldman Sachs
10
Goldman Sachs
New York
– -$107M -2,275,449 Closed
BCM
11
Beryl Capital Management
California
– -$99.5M -2,117,575 Closed
MF
12
Magnetar Financial
Illinois
– -$96.5M -2,052,642 Closed
FTCM
13
First Trust Capital Management
Illinois
– -$91.3M -1,943,767 Closed
Norges Bank
14
Norges Bank
Norway
– -$85.3M -1,815,111 Closed
Geode Capital Management
15
Geode Capital Management
Massachusetts
– -$84.1M -1,789,449 Closed
Barclays
16
Barclays
United Kingdom
– -$76.7M -1,632,615 Closed
Citigroup
17
Citigroup
New York
– -$74.8M -1,591,334 Closed
NAM
18
Nexpoint Asset Management
Texas
– -$74.4M -1,583,116 Closed
UOC
19
UBS O'Connor
Illinois
– -$65.1M -1,385,517 Closed
AllianceBernstein
20
AllianceBernstein
Tennessee
– -$63.5M -1,350,456 Closed
AA
21
AQR Arbitrage
Connecticut
– -$62M -1,319,782 Closed
Morgan Stanley
22
Morgan Stanley
New York
– -$58.6M -1,247,783 Closed
AAM
23
Alpine Associates Management
Florida
– -$54M -1,149,000 Closed
JP Morgan Chase
24
JP Morgan Chase
New York
– -$54M -1,148,914 Closed
Principal Financial Group
25
Principal Financial Group
Iowa
– -$47.1M -1,003,400 Closed
1
2 3 4 5

SWTX Hedge Fund Activity: Q3 2025 in Review

3 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q3 2025, worth a combined $2.16M — down 100% from $3.53B a quarter earlier.

Sellers outnumbered buyers: 217 funds closed out of SWTX and 0 opened new positions — a net loss of 217 holders — while 2 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $341M sold.

  • 3 institutional investors held SpringWorks Therapeutics (SWTX) as of Q3 2025, down from 222 in Q2 2025.
  • Funds reported $2.16M of SpringWorks Therapeutics stock for Q3 2025, down 100% quarter-over-quarter.
  • 0 funds opened new SpringWorks Therapeutics positions in Q3 2025 and 217 closed out, a net change of -217 holders.
  • The largest SpringWorks Therapeutics seller in Q3 2025 was BlackRock, an estimated $341M sold.

Based on aggregated 13F filings for Q3 2025.